Weathering the Storm: How Age and Biologics Influence the COVID-19 Cytokine Surge
Open Access
Abstract
SARS-CoV-2, first identified in December 2019, caused a global pandemic, resulting in over 6.8 million deaths by March 2023. The elderly, or individuals over 65, accounted for the majority of COVID-19 deaths, with 81% of fatalities in the US in 2020 occurring in this group. Beyond mortality, aging populations are also at higher risk of long-term cardiovascular complications and acute respiratory distress syndrome (ARDS). Although these outcomes may be influenced by comorbidities common in the elderly, age has been found to be a standalone risk factor for severe COVID-19 infection. Therefore, investigating age-related factors in COVID-19 outcomes is crucial in protecting this vulnerable group. Of particular interest is the cytokine storm phenomenon, an excessive inflammatory response that contributes to severe COVID-19 symptoms, including ARDS and cardiovascular damage. Elevated levels of multiple cytokines are common in severe cases of COVID-19. We propose that changes that occur to cytokine profiles as we age may contribute to these aberrant inflammatory responses. This review specifically explored the interleukin class cytokines IL-1, IL-6, IL-17, and IL-23 and considered the potential of biologics targeting these cytokines to alleviate severe outcomes in both COVID-19 and aging individuals.Keywords
This publication has 112 references indexed in Scilit:
- Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19JAMA Network Open, 2023
- The role of cytokines and their antagonists in the treatment of COVID‐19 patientsReviews in Medical Virology, 2022
- Systemic Inflammation May Induce Cardiac Injury in COVID-19 Patients Including Children and Adolescents Without Underlying Cardiovascular Diseases: A Systematic ReviewCardiovascular Revascularization Medicine, 2022
- Long-term cardiovascular adverse events in very elderly COVID-19 patientsArchives of Gerontology and Geriatrics, 2022
- A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19Immunity, Inflammation and Disease, 2021
- COVIDOSE: A Phase II Clinical Trial of Low‐Dose Tocilizumab in the Treatment of Noncritical COVID‐19 PneumoniaClinical Pharmacology & Therapeutics, 2020
- Expression of Concern: Th17 and Treg cells function in SARS‐CoV2 patients compared with healthy controlsJournal of Cellular Physiology, 2020
- Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based reviewRheumatology International, 2020
- Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Dermatology and Therapy, 2020
- Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanismsAutoimmunity Reviews, 2020